MAPT and Alzheimer disease: There were also no precise diagnostic assessments or measurements of established AD biomarkers, such as PET brain Aβ or tau PET imaging, CSF Aβ or phosphorylated tau, CSF total tau, or fluorodeoxyglucose (FDG) PET hypometabolism.